Related references
Note: Only part of the references are listed.A review of glioblastoma immunotherapy
Ravi Medikonda et al.
JOURNAL OF NEURO-ONCOLOGY (2021)
Concurrent Dexamethasone Limits the Clinical Benefit of Immune Checkpoint Blockade in Glioblastoma
J. Bryan Iorgulescu et al.
CLINICAL CANCER RESEARCH (2021)
Meningeal lymphatic vessels regulate brain tumor drainage and immunity
Xueting Hu et al.
CELL RESEARCH (2020)
Rindopepimut with Bevacizumab for Patients with Relapsed EGFRvIII-Expressing Glioblastoma (ReACT): Results of a Double-Blind Randomized Phase II Trial
David A. Reardon et al.
CLINICAL CANCER RESEARCH (2020)
VEGF-C-driven lymphatic drainage enables immunosurveillance of brain tumours
Eric Song et al.
NATURE (2020)
cIMPACT-NOW update 6: new entity and diagnostic principle recommendations of the cIMPACT-Utrecht meeting on future CNS tumor classification and grading
David N. Louis et al.
BRAIN PATHOLOGY (2020)
INO-5401 and INO-9012 delivered intramuscularly (IM) with electroporation (EP) in combination with cemiplimab (REGN2810) in newly diagnosed glioblastoma (GBM): Interim results.
David A. Reardon et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Effect of Nivolumab vs Bevacizumab in Patients With Recurrent Glioblastoma The CheckMate 143 Phase 3 Randomized Clinical Trial
David A. Reardon et al.
JAMA ONCOLOGY (2020)
Adult immuno-oncology: using past failures to inform the future
Maryam Rahman et al.
NEURO-ONCOLOGY (2020)
Once, Twice, Three Times a Finding: Reproducibility of Dendritic Cell Vaccine Trials Targeting Cytomegalovirus in Glioblastoma
Kristen A. Batich et al.
CLINICAL CANCER RESEARCH (2020)
Recent advances in mRNA vaccine technology
Norbert Pardi et al.
CURRENT OPINION IN IMMUNOLOGY (2020)
Efficacy and safety of dendritic cell vaccines for patients with glioblastoma: A meta-analysis of randomized controlled trials
Li Lv et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2020)
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies
Stephen M. Ansell et al.
BLOOD ADVANCES (2020)
Key Parameters of Tumor Epitope Immunogenicity Revealed Through a Consortium Approach Improve Neoantigen Prediction
Daniel K. Wells et al.
CELL (2020)
Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy
Gavin P. Dunn et al.
NEURO-ONCOLOGY (2020)
T cell receptor repertoire as a prognosis marker for heat shock protein peptide complex-96 vaccine trial against newly diagnosed glioblastoma
Yang Zhang et al.
ONCOIMMUNOLOGY (2020)
Brain immunology and immunotherapy in brain tumours
John H. Sampson et al.
NATURE REVIEWS CANCER (2020)
Immunotherapy in CNS cancers: the role of immune cell trafficking
Nivedita M. Ratnam et al.
NEURO-ONCOLOGY (2019)
Current State of Immunotherapy for Treatment of Glioblastoma
Tresa McGranahan et al.
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2019)
Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma
Timothy F. Cloughesy et al.
NATURE MEDICINE (2019)
Challenges to curing primary brain tumours
Kenneth Aldape et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2019)
Phase I/II trial testing safety and immunogenicity of the multipeptide IMA950/poly-ICLC vaccine in newly diagnosed adult malignant astrocytoma patients
Denis Migliorini et al.
NEURO-ONCOLOGY (2019)
Recent success and limitations of immune checkpoint inhibitors for cancer: a lesson from melanoma
Margaret Ottaviano et al.
VIRCHOWS ARCHIV (2019)
Cancer DNA vaccines: current preclinical and clinical developments and future perspectives
Alessandra Lopes et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2019)
A Characterization of Dendritic Cells and Their Role in Immunotherapy in Glioblastoma: From Preclinical Studies to Clinical Trials
Siddhartha Srivastava et al.
CANCERS (2019)
A Randomized Double-Blind Placebo-Controlled Phase II Trial of Dendritic Cell Vaccine ICT-107 in Newly Diagnosed Patients with Glioblastoma
Patrick Y. Wen et al.
CLINICAL CANCER RESEARCH (2019)
Genetic and molecular epidemiology of adult diffuse glioma
Annette M. Molinaro et al.
NATURE REVIEWS NEUROLOGY (2019)
Best practices for bioinformatic characterization of neoantigens for clinical utility
Megan M. Richters et al.
GENOME MEDICINE (2019)
Actively personalized vaccination trial for newly diagnosed glioblastoma
Norbert Hilf et al.
NATURE (2019)
Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial
Derin B. Keskin et al.
NATURE (2019)
INO-5401 and INO-9012 delivered by electroporation (EP) in combination with cemiplimab (REGN2810) in newly-diagnosed glioblastoma (GBM) (NCT03491683)
David Reardon et al.
CANCER RESEARCH (2019)
Agonist OX40 immunotherapy improves survival in glioma-bearing mice and is complementary with vaccination with irradiated GM-CSF-expressing tumor cells
Nusrat Jahan et al.
NEURO-ONCOLOGY (2018)
Vaccination in the immunotherapy of glioblastoma
Ziren Kong et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Disrupting CD47-SIRP alpha axis alone or combined with autophagy depletion for the therapy of glioblastoma
Xuyao Zhang et al.
CARCINOGENESIS (2018)
Immunotherapy of Primary Brain Tumors: Facts and Hopes
Robin A. Buerki et al.
CLINICAL CANCER RESEARCH (2018)
First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma
Linda M. Liau et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2018)
Current state of immunotherapy for glioblastoma
Michael Lim et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
mRNA vaccines - a new era in vaccinology
Norbert Pardi et al.
NATURE REVIEWS DRUG DISCOVERY (2018)
Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide
Serena Pellegatta et al.
ONCOIMMUNOLOGY (2018)
Dexamethasone-induced immunosuppression: mechanisms and implications for immunotherapy
Amber J. Giles et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
A mutation-specific peptide vaccine targeting IDH1R132H in patients with newly diagnosed malignant astrocytomas: A first-in-man multicenter phase I clinical trial of the German Neurooncology Working Group (NOA-16)
Michael Platten et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
Sequestration of T cells in bone marrow in the setting of glioblastoma and other intracranial tumors
Pakawat Chongsathidkiet et al.
NATURE MEDICINE (2018)
CNS lymphatic drainage and neuroinflammation are regulated by meningeal lymphatic vasculature
Antoine Louveau et al.
NATURE NEUROSCIENCE (2018)
Vaccine-Based Immunotherapeutics for the Treatment of Glioblastoma: Advances, Challenges, and Future Perspectives
Joshua A. Cuoco et al.
WORLD NEUROSURGERY (2018)
ATIM-41. PHASE II TRIAL OF A SURVIVIN VACCINE (SurVaxM) For Newly Diagnosed Glioblastoma
Manmeet Ahluwalia et al.
NEURO-ONCOLOGY (2018)
Audencel Immunotherapy Based on Dendritic Cells Has No Effect on Overall and Progression-Free Survival in Newly Diagnosed Glioblastoma: A Phase II Randomized Trial
Johanna Buchroithner et al.
CANCERS (2018)
Heat shock protein peptide complex-96 vaccination for newly diagnosed glioblastoma: a phase I, single-arm trial
Nan Ji et al.
JCI INSIGHT (2018)
Predicting the response to CTLA-4 blockade by longitudinal noninvasive monitoring of CD8 T cells
Mohammad Rashidian et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2017)
A phase II trial of autologous dendritic cell vaccination and radiochemotherapy following fluorescence-guided surgery in newly diagnosed glioblastoma patients
Susana Inoges et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2017)
Efficacy and safety of bevacizumab treatment for refractory brain edema: Case report
Xiangying Meng et al.
MEDICINE (2017)
Vaccine-based immunotherapeutic approaches to gliomas and beyond
Michael Weller et al.
NATURE REVIEWS NEUROLOGY (2017)
Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors
Sharareh Gholamin et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
The development of dendritic cell vaccine-based immunotherapies for glioblastoma
David A. Reardon et al.
SEMINARS IN IMMUNOPATHOLOGY (2017)
TIGIT: A Key Inhibitor of the Cancer Immunity Cycle
Nicholas A. Manieri et al.
TRENDS IN IMMUNOLOGY (2017)
Integrating Next-Generation Dendritic Cell Vaccines into the Current Cancer Immunotherapy Landscape
Abhishek D. Garg et al.
TRENDS IN IMMUNOLOGY (2017)
Recurrent glioma clinical trial, CheckMate-143: the game is not over yet
Anna C. Filley et al.
ONCOTARGET (2017)
Immunological targeting of CD133 in recurrent glioblastoma: A multicenter phase I translational and clinical study of autologous CD133 dendritic cell immunotherapy.
Jeremy David Rudnick et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Long-term Survival in Glioblastoma with Cytomegalovirus pp65-Targeted Vaccination
Kristen A. Batich et al.
CLINICAL CANCER RESEARCH (2017)
Glioblastoma Eradication Following Immune Checkpoint Blockade in an Orthotopic, Immunocompetent Model
David A. Reardon et al.
CANCER IMMUNOLOGY RESEARCH (2016)
The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
David N. Louis et al.
ACTA NEUROPATHOLOGICA (2016)
CTLA-4 and PD-1 Pathways Similarities, Differences, and Implications of Their Inhibition
Elizabeth I. Buchbinder et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2016)
Clinical study of a survivin long peptide vaccine (SurVaxM) in patients with recurrent malignant glioma
Robert A. Fenstermaker et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2016)
Novel vaccines for glioblastoma: clinical update and perspective
Evan K. Winograd et al.
IMMUNOTHERAPY (2016)
Association of WT1 IgG antibody against WT1 peptide with prolonged survival in glioblastoma multiforme patients vaccinated with WT1 peptide
Yusuke Oji et al.
INTERNATIONAL JOURNAL OF CANCER (2016)
Adjuvants for peptide-based cancer vaccines
Hiep Khong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo
Michael Zhang et al.
PLOS ONE (2016)
Immune Evasion Strategies of Glioblastoma
Seyed-Mostafa Razavi et al.
FRONTIERS IN SURGERY (2016)
Timing of surgery and bevacizumab therapy in neurosurgical patients with recurrent high grade glioma
Daniela Alexandru Abrams et al.
JOURNAL OF CLINICAL NEUROSCIENCE (2015)
Heat shock protein vaccines against glioblastoma: from bench to bedside
Leonel Ampie et al.
JOURNAL OF NEURO-ONCOLOGY (2015)
Dendritic cell-based immunotherapy targeting Wilms' tumor 1 in patients with recurrent malignant glioma
Keiichi Sakai et al.
JOURNAL OF NEUROSURGERY (2015)
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patients
Duane A. Mitchell et al.
NATURE (2015)
Structural and functional features of central nervous system lymphatic vessels
Antoine Louveau et al.
NATURE (2015)
VISTA Is an Immune Checkpoint Molecule for Human T Cells
J. Louise Lines et al.
CANCER RESEARCH (2014)
Antigen-Specific Immune Responses and Clinical Outcome After Vaccination With Glioma-Associated Antigen Peptides and Polyinosinic-Polycytidylic Acid Stabilized by Lysine and Carboxymethylcellulose in Children With Newly Diagnosed Malignant Brainstem and Nonbrainstem Gliomas
Ian F. Pollack et al.
JOURNAL OF CLINICAL ONCOLOGY (2014)
A vaccine targeting mutant IDH1 induces antitumour immunity
Theresa Schumacher et al.
NATURE (2014)
Heat-shock protein peptide complex-96 vaccination for recurrent glioblastoma: a phase II, single-arm trial
Orin Bloch et al.
NEURO-ONCOLOGY (2014)
A Randomized Trial of Bevacizumab for Newly Diagnosed Glioblastoma
Mark R. Gilbert et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
The effect of mannitol on intraoperative brain relaxation in patients undergoing supratentorial tumor surgery: study protocol for a randomized controlled trial
Yuming Peng et al.
TRIALS (2014)
HIV DNA Vaccine: Stepwise Improvements Make a Difference
Barbara K. Felber et al.
VACCINES (2014)
Therapeutic vaccination against autologous cancer stem cells with mRNA-transfected dendritic cells in patients with glioblastoma
Einar Osland Vik-Mo et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Synthetic DNA vaccines: improved vaccine potency by electroporation anc co-delivered genetic adjuvants
Seleeke Flingai et al.
FRONTIERS IN IMMUNOLOGY (2013)
Mannitol for acute traumatic brain injury
Abel Wakai et al.
COCHRANE DATABASE OF SYSTEMATIC REVIEWS (2013)
Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial
Hilko Ardon et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Magalie Dosset et al.
CLINICAL CANCER RESEARCH (2012)
Induction of Abscopal Anti-Tumor Immunity and Immunogenic Tumor Cell Death by Ionizing Irradiation - Implications for Cancer Therapies
B. Frey et al.
CURRENT MEDICINAL CHEMISTRY (2012)
Peptide-pulsed dendritic cell vaccination targeting interleukin-13 receptor α2 chain in recurrent malignant glioma patients with HLA-A*24/A*02 allele
Kenichiro Iwami et al.
CYTOTHERAPY (2012)
Use of 11C-methionine PET parametric response map for monitoring WT1 immunotherapy response in recurrent malignant glioma Clinical article
Yasuyoshi Chiba et al.
JOURNAL OF NEUROSURGERY (2012)
Harnessing DNA-induced immune responses for improving cancer vaccines
Andres A. Herrada et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2012)
CpG DNA as a vaccine adjuvant
Christian Bode et al.
EXPERT REVIEW OF VACCINES (2011)
Immune Response in Patients With Newly Diagnosed Glioblastoma Multiforme Treated With Intranodal Autologous Tumor Lysate-dendritic Cell Vaccination After Radiation Chemotherapy
Camilo E. Fadul et al.
JOURNAL OF IMMUNOTHERAPY (2011)
MR perfusion and diffusion imaging in the follow-up of recurrent glioblastoma treated with dendritic cell immunotherapy: a pilot study
Matej Vrabec et al.
NEURORADIOLOGY (2011)
Heat shock proteins: Cellular and molecular mechanisms in the central nervous system
R. Anne Stetler et al.
PROGRESS IN NEUROBIOLOGY (2010)
An epidermal growth factor receptor variant III-targeted vaccine is safe and immunogenic in patients with glioblastoma multiforme
John H. Sampson et al.
MOLECULAR CANCER THERAPEUTICS (2009)
Vaccination against HPV-16 Oncoproteins for Vulvar Intraepithelial Neoplasia.
Gemma G. Kenter et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Vaccination elicits correlated immune and clinical responses in glioblastoma multiforme patients
Christopher J. Wheeler et al.
CANCER RESEARCH (2008)
Phase II clinical trial of Wilms tumor 1 peptide vaccination for patients with recurrent glioblastoma multiforme
Shuichi Izumoto et al.
JOURNAL OF NEUROSURGERY (2008)
The heat shock response and Chaperones/Heat shock proteins in brain tumors: Surface expression, release, and possible immune consequences
Michael W. Graner et al.
JOURNAL OF NEUROSCIENCE (2007)
Vaccines in cancer:: GVAX®, a GM-CDF gene vaccine
John Nemunaitis
EXPERT REVIEW OF VACCINES (2005)
Essential role of CD91 in re-presentation of gp96-chaperoned peptides
RJ Binder et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2004)
Established human papillomavirus type 16-expressing tumors are effectively eradicated following vaccination with long peptides
S Zwaveling et al.
JOURNAL OF IMMUNOLOGY (2002)
Three-step purification of gp96 from human liver tumor tissues suitable for isolation of gp96-bound peptides
SD Meng et al.
JOURNAL OF IMMUNOLOGICAL METHODS (2002)
TNF receptor I is required for induction of macrophage heat shock protein 70
JK Heimbach et al.
AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY (2001)
CD91 is a common receptor for heat shock proteins gp96, hsp90, hsp70, and calreticulin
S Basu et al.
IMMUNITY (2001)
Expression and functional activity of heat shock proteins in human glioblastoma multiforme
M Hermisson et al.
NEUROLOGY (2000)
Share Paper
